Phase 3 study for people with Bladder Cancer

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor Bristol-Myers Squibb
Registry number NCT07106762
Started 30 September 2025 Today 16 October 2026 Estimated completion 26 January 2029

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Macquarie University Macquarie University NSW Recruiting
GenesisCare North Shore St Leonards NSW Recruiting
Austin Health Heidelberg VIC Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 470

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Participants must have histologically confirmed advanced urothelial carcinoma.

* Participants must be eligible to receive platinum-based chemotherapy.

* Participants must be Anti-PD-(L)1-experienced (in locally advanced or metastatic setting), either in combination with or sequential to another systemic therapy.

* Participants treated only in the peri-operative setting must have relapsed within 12 months of the last dose of the treatment.

* Participants must have ≥ 1 measurable lesion per RECIST v1.1.

* Participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

Exclusion Criteria:

* Participants must not have platinum-based chemotherapy exposure within 12 months.

* Participants must not have received \>2 prior regimens irrespective of the setting.

* Participants must not have prior ADC therapy targeting EGFR or HER3.

* Participants must not have prior therapy with topoisomerase 1 inhibitor.

* Participants must not have active, untreated brain metastases.

* Other protocol-defined inclusion/exclusion criteria apply.

Dates on the record

Started 30 September 2025
Estimated completion 26 January 2029
Registry last updated 29 July 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 29 July 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.